Laurus Labs Hits Record High on Strong Q2 Results and CDMO Expansion
Laurus Labs shares surged nearly 6% to a record high after reporting Q2 FY27 revenue growth of 33% and a more than doubling of net profit, driven by its expanding CDMO platform.

Laurus Labs share price climbed nearly 6% to a record high of ₹2,381.15 on Friday, October 30, after reporting strong September-quarter results. The stock has now rebounded 161% from its 52-week low of ₹913.35, recorded on February 2, 2026. The Hyderabad-based company's consolidated revenue from operations increased to ₹2,206 crore in Q2 FY27, compared with ₹1,653 crore in the corresponding quarter last year. On a sequential basis, revenue grew about 8.9% from ₹2,026 crore in Q1 FY27.
Net profit more than doubled, surging 126% year-on-year to ₹441 crore from ₹195 crore. Compared with the previous quarter, profit rose about 20.2%. The company also declared an interim dividend of ₹1 per equity share of ₹2 face value.
Earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased to ₹762 crore from ₹429 crore a year ago. The EBITDA margin stood at 34.5%, while the gross margin expanded to 63% from 59.9%. For the first half of FY27, revenue rose 31% year-on-year to ₹4,233 crore, with EBITDA at ₹1,406 crore and a margin of 33.2%.
Dr Satyanarayana Chava said the company had delivered another record quarter in revenue and profitability.
Capacity and technology expansion
Laurus Labs is scaling its peptide and oligonucleotide capabilities through new plants and targeted acquisitions. The company has operationalised its first commercial-scale peptide manufacturing plant in Vizag, using new operating systems. A significant capacity expansion is already in progress to address surging demand for peptide therapeutics.
The company made targeted investments in oligonucleotides and peptide-resins technologies, raising its integrated contract development and manufacturing organisation (CDMO) offering. Laurus Labs plans capital expenditure of more than ₹30 billion over FY27-FY28, largely targeting these high-growth projects.
In line with this strategy, the Board approved the acquisition of a 52% stake in Hyderabad-based SI & C Resins at a pre-money valuation of ₹30 crore. Laurus proposes to invest a total of ₹32.50 crore in the company, which specialises in manufacturing high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries.
Analyst actions and valuation
Mixed analyst views emerged following the results. Jefferies maintained its HOLD rating while raising its target price to ₹2,100 from ₹1,700. The firm raised its FY27 and FY28 earnings-per-share estimates by 6% and 4%, respectively. Jefferies highlighted the company's peptide manufacturing capacity of 16,000 litres, with commercial revenues expected from the second half of FY28 or FY29. The analysts noted, "Q2 revenue grew 33% year-on-year and EBITDA rose 86%, taking the margin to 34%."
In contrast, Kotak maintained its SELL rating with a fair value of ₹1,400. While it expects EBITDA to grow at a compound annual growth rate of around 34% over FY26-FY29, with margins potentially reaching 36% by FY29, the firm flagged valuation concerns despite opportunities in peptides, oligonucleotides and advanced therapies.
Capital allocation and future pipeline
Significant planned spend and acquisition activity point to sustained investment in high-growth therapeutic areas. Laurus Labs signed an agreement to acquire a 60% stake in Canada-based biotechnology company Galenvs Sciences at a pre-money valuation of $3.5 million. The proposed investment of $3.75 million by Laurus includes a primary infusion of $2.75 million.
Galenvs specialises in custom oligonucleotide synthesis and functional magnetic-nanoparticle technologies for the diagnostics and therapeutics markets. Jamal Daoud, Founder & Chief Executive Officer of Galenvs Sciences, stated that combining oligonucleotide and magnetic nanoparticle capabilities with Laurus' infrastructure creates a strong platform to serve customers from early-stage development through scale-up and manufacturing.
The company's board will consider further capacity expansion plans in upcoming quarters.





